Drug Trial Radar · NCT01379560
A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration
Last checked: Nov 20, 2026Latest source record: Dec 10, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
May 2011
Primary completion
Dec 2011
Study completion Dec 2011
Sponsor
- Lead sponsor
- Sucampo Pharma Americas, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Sucampo Pharmaceuticals, Inc.
- First posted
- Jun 23, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the pharmacodynamics of ocular blood flow measurements with multiple drop unoprostone isopropyl administration versus placebo in subjects with dry age-related macular degeneration (AMD).
Conditions
- Dry Age-related Macular Degeneration
Interventions
unoprostone isopropylDrug
1. unoprostone isopropyl (2 drops) 2. placebo (2 drops)
unoprostone isopropylDrug
1. unoprostone isopropyl (3 drops) 2. placebo (3 drops)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in choroidal blood flowTime frame: In total 6 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical University of Vienna
Vienna, Austria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.